By blocking the checkpoint molecules such as CTLA-4, PD-1, and PD-L1 from binding with their partner proteins, ICIs inhibit the ‘off’ signal, activating T cells and promoting the killing of cancer cells. Here, CTLA4 is linked to cancer.